Skip to main content

Ocrevus Disease Interactions

There are 4 disease interactions with Ocrevus (ocrelizumab).

Major

Ocrelizumab (applies to Ocrevus) hepatitis B

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

The use of ocrelizumab is contraindicated in patients with an active hepatitis B virus (HBV) infection. It is recommended to consult a liver disease expert before starting and during treatment with ocrelizumab in patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+].

References

  1. (2017) "Product Information. Ocrevus (ocrelizumab)." Genentech
Moderate

Ocrelizumab (applies to Ocrevus) breast cancer

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neoplasia -- Estrogen Dependent

Ocrelizumab may increase the risk of malignancies, including breast cancer. It is recommended to follow standard breast cancer screening guidelines. Exercise care when using this agent in patients with a history of breast cancer or other type of malignancy. Monitor closely for the development of any sign or symptom suggestive of a malignancy and treat appropriately.

References

  1. (2017) "Product Information. Ocrevus (ocrelizumab)." Genentech
Moderate

Ocrelizumab (applies to Ocrevus) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Pleuropulmonary Infection

Ocrelizumab may increase the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections. It is recommended to delay the use of ocrelizumab in patients with an active infection until the infection is resolved.

References

  1. (2017) "Product Information. Ocrevus (ocrelizumab)." Genentech
Moderate

Ocrelizumab (applies to Ocrevus) vaccination

Moderate Potential Hazard, Moderate plausibility.

The use of live-attenuated or live vaccines is not recommended during treatment with ocrelizumab and until B-cell repletion is confirmed. It is recommended to administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ocrelizumab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of treatment for non-live vaccines. Ocrelizumab may interfere with the effectiveness of non-live vaccines.

References

  1. (2017) "Product Information. Ocrevus (ocrelizumab)." Genentech

Ocrevus drug interactions

There are 406 drug interactions with Ocrevus (ocrelizumab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer